A phase 3 randomized clinical trial (RCT), IMBRAVE150, assessed the ICI and anti-angiogenesis combination approach, employing atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGF) in treatment-naive advanced/metastatic HCC. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.